SkyBridge Pharmaceutical - About the company
SkyBridge Pharmaceutical is a funded company based in Accra (Ghana), founded in 2024 by Samuel Twumasi. It operates as a Developer of prescription and over-the-counter medications, including cannabinoid-based therapies. SkyBridge Pharmaceutical has raised an undisclosed amount in funding. The company has 1692 active competitors, including 78 funded and 177 that have exited. Its top competitors include companies like AbbVie, Amgen and Gilead.
Company Details
Developer of prescription and over-the-counter medications, including cannabinoid-based therapies. It focuses on neurological research and advanced pain management solutions. The company manufactures pharmaceuticals, ensuring regulatory compliance. It researches cannabinoid-based medicines and conducts clinical trials for neurological disorders, oncology support, chronic pain, and mental health conditions. It also provides contraceptives and pregnancy tests.
- Website
- skybridgepharmaceutical.com
- Email ID
- *****@skybridgepharmaceutical.com
- Phone Number
- +233 **********
Key Metrics
Founded Year
2024
Location
Accra, Ghana
Stage
Funding Raised
Latest Funding Round
Investors
Ranked
777th among 1692 active competitors
Sign up to download SkyBridge Pharmaceutical's company profile
SkyBridge Pharmaceutical's funding and investors
SkyBridge Pharmaceutical has raised funding over 2 rounds. Its first funding round was on Jul 10, 2009. Its latest funding round was a Grant (prize money) round on Jul 15, 2009 for $*****. 1 investor participated in its latest round. SkyBridge Pharmaceutical has 1 institutional investor.
Here is the list of recent funding rounds of SkyBridge Pharmaceutical:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jul 15, 2009 | 6023163 | Grant (prize money) | 9438947 | 8103359 | 1581524 | 2388710 |
Jul 10, 2009 | 7564630 | Grant (prize money) | 3372562 | 6893385 | 4353836 |
Access funding benchmarks and valuations. Sign up today!View details of SkyBridge Pharmaceutical's funding rounds and investors
SkyBridge Pharmaceutical's founders and board of directors
Founder? Claim ProfileThe founders of SkyBridge Pharmaceutical is Samuel Twumasi. Samuel Twumasi is the CEO of SkyBridge Pharmaceutical.
Here are the details of SkyBridge Pharmaceutical's key team members:
- Samuel Twumasi: Founder & CEO of SkyBridge Pharmaceutical.
View details of SkyBridge Pharmaceutical's Founder profiles and Board Members
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
SkyBridge Pharmaceutical's Competitors and alternates
Top competitors of SkyBridge Pharmaceutical include AbbVie, Amgen and Gilead. Here is the list of Top 10 competitors of SkyBridge Pharmaceutical, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | AbbVie 2012, Chicago (United States), Public | Research-based biopharmaceutical company | $14.7B | 81/100 | |
2nd | Amgen 1980, Thousand Oaks (United States), Public | Developer of pharmaceutical products for treating multiple diseases | - | 81/100 | |
3rd | Gilead 1987, Foster City (United States), Acquired | Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | - | 80/100 | |
4th | Lilly 1876, Indianapolis (United States), Public | Developer of traditional pharmaceutical medicines | - | 79/100 | |
5th |  Johnson & Johnson 1886, New Brunswick (United States), Public | Manufacturer and supplier of beauty care products, medical devices, and pharmaceutical products | - | 76/100 | |
6th |  AstraZeneca 1999, Cambridge (United Kingdom), Public | Developer of pharmaceutical medicines for oncology and various chronic diseases | - | 73/100 | |
7th |  Pfizer 1849, New York City (United States), Public | Provider of pharmaceutical products for multiple disease treatments | - | 72/100 | |
8th |  Roivant Sciences 2014, New York City (United States), Public | Developer of therapeutics to treat neurology, oncology, rare, and endocrinology based diseases | $1.3B | 72/100 | |
9th |  Regeneron Pharmaceuticals 1988, Tarrytown (United States), Public | Developer of antibodies for the treatment of cancer, eye diseases, inflammatory diseases & others | - | 71/100 | |
10th | Novartis 1996, Basel (Switzerland), Acquired | R&D focused on manufacturing of drugs for multiple therapeutic areas | - | 70/100 | |
777th | SkyBridge Pharmaceutical 2024, Accra (Ghana), Funding Raised | Developer of prescription and over-the-counter medications, including cannabinoid-based therapies | - | 16/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on SkyBridge Pharmaceutical's competitors? Click here to see the top ones
SkyBridge Pharmaceutical's Investments and acquisitions
SkyBridge Pharmaceutical has made no investments or acquisitions yet.
Are you a Founder ?
FAQs about SkyBridge Pharmaceutical
Explore our recently published companies
- [Bystudiokate] - United Kingdom based, Unfunded company
- Blue Wren - Preston based, 2010 founded, Seed company
- Unrival - Bristol based, 2012 founded, Seed company
- Policy in Practice - London based, 2012 founded, Seed company
- Devic - Unfunded company
- Phototune - Unfunded company
